RECRUITING

Late Onset Alzheimer's Disease

Conditions

Alzheimer Disease Genetic testing Genetic influence

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.

Official Title

Late Onset Alzheimer's Disease

Quick Facts

Study Start:2016-11-15

Study Completion:2026-09

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05010603

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:55 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases. * a living sibling with probable or possible AD; * a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older); * participants in the proband's generation with an identified companion serving as an informant; * participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent.	* failure to identify an appropriate informant; * uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder; * discovery of additional diagnosis that could account for the clinical manifestations; * unwillingness to participate; * failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD); * participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.

Inclusion Criteria

Exclusion Criteria

* Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases.
* a living sibling with probable or possible AD;
* a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older);
* participants in the proband's generation with an identified companion serving as an informant;
* participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent.

* failure to identify an appropriate informant;
* uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder;
* discovery of additional diagnosis that could account for the clinical manifestations;
* unwillingness to participate;
* failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD);
* participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.

Contacts and Locations

Study Contact

Dolly Reyes-Dumeyer

CONTACT

212-305-5953

dr2290@cumc.columbia.edu

Amanda Chan

CONTACT

917-696-3082

akc2177@cumc.columbia.edu

Principal Investigator

Richard P. Mayeux, MD, MSc

PRINCIPAL_INVESTIGATOR

Columbia University

Study Locations (Sites)

University of Washington

Washington, District of Columbia, 98105

United States

University of Miami

Miami, Florida, 33124

United States

Rush University

Aurora, Illinois, 60612

United States

Indiana University

Bloomington, Indiana, 47405

United States

NCRAD at Indiana University

Indianapolis, Indiana, 46202

United States

Mayo Clinic

Rochester, Minnesota, 55901

United States

Joanne Norton

Saint Louis, Missouri, 63130

United States

Columbia University Irving Medical Center

New York, New York, 10032

United States

North Carolina State University

Raleigh, North Carolina, 27695

United States

University of Pittsburgh

Pittsburgh, Pennsylvania, 15213

United States

University of Texas Southwestern

Dallas, Texas, 75390

United States

University of Washington

Seattle, Washington, 98195

United States

Collaborators and Investigators

Sponsor: Columbia University

Richard P. Mayeux, MD, MSc, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-11-15

Study Completion Date2026-09

Study Record Updates

Study Start Date2016-11-15

Study Completion Date2026-09

Terms related to this study

Keywords Provided by Researchers

Genetic testing
Genetic influence

Additional Relevant MeSH Terms

Alzheimer Disease